PI3K-mTOR双重小分子抑制剂的研究进展

陈颖; 韩进松; 王重庆; 宋云龙; 周永刚; 朱驹

doi:10.3969/j.issn.1006-0111.2014.05.004

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

PI3K-mTOR双重小分子抑制剂的研究进展

陈颖, 韩进松, 王重庆, 宋云龙, 周永刚, 朱驹

文章导航 > 药学实践与服务 > 2014 > 32(5): 332-336,359

陈颖, 韩进松, 王重庆, 宋云龙, 周永刚, 朱驹. PI3K-mTOR双重小分子抑制剂的研究进展[J]. 药学实践与服务, 2014, 32(5): 332-336,359. doi: 10.3969/j.issn.1006-0111.2014.05.004

引用本文:

CHEN Ying, HAN Jinsong, WANG Chongqing, SONG Yunlong, ZHOU Yonggang, ZHU Ju. Review of research on dual PI3K-mTOR small molecular inhibitors[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(5): 332-336,359. doi: 10.3969/j.issn.1006-0111.2014.05.004

Citation:

CHEN Ying, HAN Jinsong, WANG Chongqing, SONG Yunlong, ZHOU Yonggang, ZHU Ju. Review of research on dual PI3K-mTOR small molecular inhibitors[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(5): 332-336,359. doi: 10.3969/j.issn.1006-0111.2014.05.004

PI3K-mTOR双重小分子抑制剂的研究进展

doi: 10.3969/j.issn.1006-0111.2014.05.004

1.
第二军医大学药学院药物化学教研室, 上海 200433
2.
解放军81医院药剂科, 江苏南京 210002

Review of research on dual PI3K-mTOR small molecular inhibitors

1.
Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
2.
Department of Pharmacy, No. 81 Hospital of PLA, Nanjing 210002, China

摘要: PI3K脂激酶家族介导的细胞信号转导通路,调节细胞增殖、分化、凋亡等一系列活动,已经成为治疗肿瘤、炎症等疾病的重要靶标。近来出现了多种结构类型的该通路抑制剂,笔者总结了近年内进入临床研究的具有PI3K-mTOR双重抑制活性的小分子化合物。
- 磷脂酰肌醇3激酶-哺乳动物雷帕霉素靶蛋白 /
- 双重抑制剂 /
- 小分子 /
- 抗肿瘤
Abstract: Objective The phosphoinositide 3-kinase (PI3K) constituted an important family of lipid kinase enzymes that control a range of cellular proliferation, differentiation and apoptosis through their regulation of a network of signal transduction pathways, which had emerged as important therapeutic targets in the context of cancer and inflammation. Considerable progress had been made in the discovery and development of small molecular inhibitors targeting PI3K. Progress in dual PI3K-mTOR inhibitors, a number of which had entered early phase clinical trials over recent years was summarized.
- PI3K-mTOR /
- dual inhibitors /
- small molecules /
- anticancer

[1]	Vivanco I, Sawyers CL, The phosphatidylinositol 3,kinase AKT pathway in human cancer[J]. Nat Rev Cancer, 2002,2(7):489-501.
[2]	Bjornsti MA, Houghton PJ, The TOR pathway:a target for cancer therapy[J]. Nat Rev Cancer, 2004,4(5):335-348.
[3]	Workman P, Clarke PA, Raynaud FI,et al.Drugging the PI3 kinome:from chemical tools to drugs in the clinic[J]. Cancer Res, 2010,70(6):2146-2157.
[4]	Denley A, Kang S, Karst U,et al.Oncogenic signaling of class I PI3K isoforms[J]. Oncogene, 2008, 27(18):2561-2574.
[5]	Falasca M, Maffucci T, Role of class Ⅱ phosphoinositide 3-kinase in cell signalling[J]. Biochem Soc Trans, 2007,35(Pt 2):211-214.
[6]	Guertin DA, Sabatini DM. Defining the role of mTOR in cancer[J]. Cancer Cell, 2007,12(1):9-22.
[7]	Bunney TD, Katan M.Phosphoinositide signalling in cancer:beyond PI3K and PTEN[J]. Nat Rev Cancer, 2010,10(5):342-352.
[8]	Bussink J, van der Kogel AJ, Kaanders JH, Activation of the PI3,K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer[J]. Lancet Oncol, 2008,9(3):288-296.
[9]	Massion PP, Kuo WL, Stokoe D,et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization:implications of the phosphatidylinositol 3-kinase pathway[J]. Cancer Res, 2002,62(13):3636-3640.
[10]	Sutherlin DP, Bao L, Berry M,et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer[J]. J Med Chem, 2011,54(21):7579-7587.
[11]	Wu P, Hu YZ.Small molecules targeting phosphoinositide 3-kinases[J]. Med Chem Comm, 2012,3(11):1337-1355.
[12]	Garlich JR, De P, Dey N,et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity[J]. Cancer Res, 2008,68(1):206-215.
[13]	Ozbay T, Durden DL, Liu T,et al. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells[J]. Cancer Chemother Pharmacol, 2010,65(4):697-706.
[14]	Stauffer F, Maira SM, Furet P,et al. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway[J]. Bioorg Med Chem Lett, 2008,18(3):1027-1030.
[15]	Knight SD, Adams ND, Burgess JL,et al. Discovery of GSK2126458, a highly potent Inhibitor of PI3K and the mammalian target of rapamycin[J]. Acs Med Chem Lett, 2010,1(1):39-43.
[16]	Venkatesan AM, Dehnhardt CM, Delos SE,et al. Bis(morpholino-1,3,5-triazine)derivatives:potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors:discovery of compound 26(PKI-587), a highly efficacious dual Inhibitor[J]. J Med Chem, 2010,53(6):2636-2645.
[17]	Dehnhardt CM, Venkatesan AM, Delos SE,et al. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors:discovery of PKI-402[J]. J Med Chem, 2010,53(2):798-810.
[18]	Mallon R, Feldberg LR, Lucas J, et al.Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor[J]. Clin Cancer Res, 2011,17(10):3193-3203.
[19]	Cheng HM, Bagrodia S, Bailey S,et al. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design[J]. Med Chem Comm, 2010,1(2):139-144.
[20]	Markman B, Tabernero J,Krop I,et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors[J]. Ann Oncol, 2012,23(9):2399-2408.
[21]	Heffron TP, Berry M, Castanedo G,et al. Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor[J]. Bioorg Med Chem Lett, 2010,20(8):2408-2411.
[22]	Kashiyama T, Oda K, Ikeda Y,et al.Antitumor efficacy of DS-7423, a novel PI3K/mTOR dual inhibitor, in ovarian clear cell adenocarcinoma[J]. Eur J Cancer, 2012,48:110-111.

[1]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
[2]	陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠. UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(8): 341-345. doi: 10.12206/j.issn.2097-2024.202404082
[3]	李想, 陆鸿远, 张明玉, 高欢, 姚东, 许子华. 米格列醇激活UCP1介导棕色脂肪对冷暴露小鼠损伤的研究 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404005
[4]	陈炳辰, 王思真, 郭贝贝, 杨峰. 紫杉醇棕榈酸酯的合成及其脂质体的制备与处方研究 . 药学实践与服务, 2024, 42(9): 379-384, 410. doi: 10.12206/j.issn.2097-2024.202404062
[5]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
[6]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[7]	杨嘉宁, 赵一颖, 肖伟. 七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
[8]	杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛. 正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
[9]	陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾. 基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
[10]	陈金涛, 乔子婴, 马明华, 张若曦, 王振伟, 年华. 基于网络药理学和分子对接技术研究金芪清疏颗粒治疗社区获得性肺炎的潜在机制 . 药学实践与服务, 2024, 42(11): 471-478. doi: 10.12206/j.issn.2097-2024.202312014
[11]	崔亚玲, 吴琼, 马良煜, 胡北, 姚东, 许子华. 肝素钠肌醇烟酸酯乳膏中肌醇烟酸酯皮肤药动学研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404006
[12]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[13]	张成中, 朱雪艳, 卜其涛, 王宏瑞, 黄宝康. 基于网络药理学与分子对接预测鸡骨草特征图谱研究 . 药学实践与服务, 2024, 42(8): 350-358. doi: 10.12206/j.issn.2097-2024.202303048
[14]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[15]	刘汝雄, 杨万镇, 涂杰, 盛春泉. 铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075